Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228772 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02228772: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT02228772 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02228772, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This research study is evaluating a combination of drugs considered standard treatment for children and young adults with acute lymphoblastic leukemia (ALL), in combination with a new drug called MLN 9708. Additionally, the study is also evaluating if bone marrow or stem cell transplantation, which will be given to some participants, helps to prevent ALL from returning.
Interventions
- DRUG Doxorubicin
- DRUG Vincristine
- DRUG Cytarabine
- DRUG Mercaptopurine
- DRUG MLN 9708
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-12 |
| Est. Completion | 2019-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228772
The ClinicalTrials.gov registry entry for NCT02228772 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT02228772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02228772 about?
NCT02228772 is a clinical study titled "Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults". This research study is evaluating a combination of drugs considered standard treatment for children and young adults with acute lymphoblastic leukemia (ALL), in combination with a new drug called MLN 9708. Additionally, the study is also evaluating if bone marrow or stem cell transplantation, which ...
What is the current status of trial NCT02228772?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-12. Estimated completion is 2019-11.
What interventions are being tested in trial NCT02228772?
The interventions under investigation include: Doxorubicin (DRUG), Vincristine (DRUG), Cytarabine (DRUG), Mercaptopurine (DRUG), MLN 9708 (DRUG).
Who is sponsoring clinical trial NCT02228772?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.